Factor VIII inhibitors are produced during or after coagulation factor VIII (FVIII) therapy in hemophilia A patients. These inhibitors are usually detected by a modified Bethesda assay or an enzymelinked immunosorbent assay (ELISA). In this study, we used the Bethesda assay to determine the incidence of FVIII inhibitors in 75 fresh plasma samples obtained from 50 hemophilia A patients, and then used ELISA and the Bethesda assay to determine the titres of these inhibitors after the samples had been frozen and thawed. The samples from the screening Bethesda assay were centrifuged and stored at -70℃in accordance with the assay guidelines. Subsequently, these samples were thawed and analyzed using ELISA and the Bethesda assay. The incidence of inhibitors in hemophilia A patients was 20.0%. Among the 35 inhibitor-positive samples identified in the screening Bethesda assay, 16 were positive in ELISA while only 4 were positive in the repeated Bethesda assay. In this study, the ELISA technique showed a higher sensitivity than the Bethesda assay in the detection of FVIII inhibitors in samples that were subjected to freezing and thawing procedures; this was because the Bethesda assay could not identify the FVIII inhibitors that were degraded after freezing and thawing. (Korean J Lab Med 2010;30:260-3) 
Factor VIII inhibitors are produced during or after coagulation factor VIII (FVIII) therapy in hemophilia A patients. These inhibitors are usually detected by a modified Bethesda assay or an enzymelinked immunosorbent assay (ELISA). In this study, we used the Bethesda assay to determine the incidence of FVIII inhibitors in 75 fresh plasma samples obtained from 50 hemophilia A patients, and then used ELISA and the Bethesda assay to determine the titres of these inhibitors after the samples had been frozen and thawed. The samples from the screening Bethesda assay were centrifuged and stored at -70℃in accordance with the assay guidelines. Subsequently, these samples were thawed and analyzed using ELISA and the Bethesda assay. The incidence of inhibitors in hemophilia A patients was 20.0%. Among the 35 inhibitor-positive samples identified in the screening Bethesda assay, 16 were positive in ELISA while only 4 were positive in the repeated Bethesda assay. In this study, the ELISA technique showed a higher sensitivity than the Bethesda assay in the detection of FVIII inhibitors in samples that were subjected to freezing and thawing procedures; this was because the Bethesda assay could not identify the FVIII inhibitors that were degraded after freezing and thawing. Table 1 ). The Bethesda assay to determine the inhibitor titre was repeated after freezing and thawing; in the second Bethesda assay, only 4 samples (N=4) were positive ( Table 1 ). The titres obtained in the Bethesda screening assay were between 1.3 and 2.7 BU/mL, but those obtained during the repeated assay were between 0.8 and 1.4 BU/mL.
In the repeated Bethesda assay, 12 samples showed negative results. In the initial Bethesda assay, these 12 samples were positive for FVIII inhibitors with inhibitor titres less than 1.7 BU/mL, thereby indicating titres at the borderline levels. The 2 samples with high ELISA titres (>900) were obtained from patients whose Bethesda assay titres were 1.7 and 0.6 BU/mL.
Of the 19 samples that were positive in the Bethesda screening assay but not detected in ELISA showed low titres that were around the borderline, and only 1 had a titre higher than the borderline.
Using the Bethesda screening assay, positive titres were confirmed in 10 of the 50 patients enrolled in our study; thus, the antibody incidence was 20.0%, which was higher than the overall incidence of 12.5% in Korea [6] . However, these values vary widely [7] [8] [9] [10] [11] [12] , because the FVIII inhibitor profile of Korean patients may be different from that of patients in other countries, and differences may exist even among the Korean hemophilic patients. In addition, if a lupus-sensitive activated partial thromboplastin time (aPTT) reagent is used, the Bethesda assay will show positive titres in lupus-anticoagulant patients [13] . The Bethesda assay may also be affected by thrombin inhibitors [5, 14] , although we could not assess the presence of lupus anticoagulants or thrombin inhibitors in our samples. with the findings of the previous studies [15, 16] .
Although studies have shown that plasma samples can be frozen at -70℃ without affecting the activity of FVIII inhibitors [17, 18] , samples with borderline titres (between 0.3 BU/mL and 0.7 BU/mL) in the Bethesda screening assay were negative in the repeated Bethesda assay performed after thawing the sample. Moreover, the titre levels in the repeated Bethesda assay performed after thawing were lower than those in the Bethesda screening assay, thereby suggesting that antibodies in the samples undergo degradation during freezing and thawing and lead to titres below the detection level in the repeated Bethesda assay.
In this study, the ELISA technique showed a higher sensitivity than the Bethesda assay in the detection of FVIII inhibitors in samples subjected to freezing and thawing procedures. This finding is consistent with those of previous studies [1, 19] . Therefore, ELISA can be considered as a sensitive screening method for determining FVIII inhibitors in samples subjected to freezing and thawing procedures. Moreover, ELISA is an efficient technique for the detection of low titres of inhibitors.
